ES2115267T3 - Compuestos de 26,28-metilen-1alfa,25-dihidroxivitamina d2. - Google Patents

Compuestos de 26,28-metilen-1alfa,25-dihidroxivitamina d2.

Info

Publication number
ES2115267T3
ES2115267T3 ES94931967T ES94931967T ES2115267T3 ES 2115267 T3 ES2115267 T3 ES 2115267T3 ES 94931967 T ES94931967 T ES 94931967T ES 94931967 T ES94931967 T ES 94931967T ES 2115267 T3 ES2115267 T3 ES 2115267T3
Authority
ES
Spain
Prior art keywords
compounds
dihydroxivitamine
1alpha
methylene
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94931967T
Other languages
English (en)
Inventor
Hector F Deluca
Naoshi Nakagawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Application granted granted Critical
Publication of ES2115267T3 publication Critical patent/ES2115267T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ANALOGOS DE VITAMINA D 2 EN LOS QUE SE INTRODUCE UN ANILLO DE CICLOPENTANO EN LA CADENA LATERAL DE 1{AL},25 DIHIDROXIVITAMINA D{SUB,2}. LOS COMPUESTOS SE CARACTERIZAN POR UNA ACTIVIDAD DE TRANSPORTE DE CALCIO INTESTINAL MARCADA MIENTRAS MUESTRAN ACTIVIDAD MUCHO MAS BAJA QUE 1{AL},25 DIHIDROXIVITAMINA D{SUB,3} EN SU CAPACIDAD PARA MOVILIZAR CALCIO DEL HUESO. DEBIDO A SU ACTIVIDAD CALCEMICA PREFERENTE, ESTOS COMPUESTOS SERIAN UTILES PARA EL TRATAMIENTO DE ENFERMEDADES DONDE SE DESEE LA FORMACION OSEA, COMO OSTEOPOROSIS.
ES94931967T 1993-11-24 1994-10-19 Compuestos de 26,28-metilen-1alfa,25-dihidroxivitamina d2. Expired - Lifetime ES2115267T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/157,970 US5373004A (en) 1993-11-24 1993-11-24 26,28-methylene-1α, 25-dihydroxyvitamin D2 compounds

Publications (1)

Publication Number Publication Date
ES2115267T3 true ES2115267T3 (es) 1998-06-16

Family

ID=22566140

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94931967T Expired - Lifetime ES2115267T3 (es) 1993-11-24 1994-10-19 Compuestos de 26,28-metilen-1alfa,25-dihidroxivitamina d2.

Country Status (9)

Country Link
US (2) US5373004A (es)
EP (1) EP0730577B1 (es)
JP (1) JP3681390B2 (es)
AT (1) ATE165819T1 (es)
AU (1) AU8086494A (es)
DE (1) DE69410112T2 (es)
DK (1) DK0730577T3 (es)
ES (1) ES2115267T3 (es)
WO (1) WO1995014662A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040167106A1 (en) * 1993-06-04 2004-08-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of a Vitamin D compound
US6407082B1 (en) 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
CN1090180C (zh) * 1997-06-25 2002-09-04 帝人株式会社 维生素d3衍生物及其用于炎性呼吸道疾病的治疗剂
WO2000038692A1 (fr) * 1998-12-24 2000-07-06 Teijin Limited Remedes contre la mucoviscidose contenant des derives de la vitamine d¿3?
US6479474B2 (en) * 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
BR0107479A (pt) 2000-01-10 2002-09-03 Leo Pharma As Composto, composição farmacêutica, uso de um composto, e, método para o tratamento e/ou profilaxia de doenças
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
JP2004511435A (ja) * 2000-07-27 2004-04-15 ファルマシア・コーポレーション うっ血性心不全の処置のための、エポキシ−ステロイド型アルドステロン拮抗薬とβ−アドレナリン作動性拮抗薬の併用療法
EP2393494A1 (en) 2009-01-27 2011-12-14 Berg Biosystems, LLC Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
CA2770683C (en) 2009-08-14 2018-09-04 Berg Biosystems, Llc Vitamin d3 and analogs thereof for treating alopecia
SG10201709894RA (en) 2013-05-29 2018-01-30 Berg Llc Preventing or mitigating chemotherapy induced alopecia using vitamin d

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3247836A1 (de) * 1981-12-29 1983-07-07 Teijin Ltd., Osaka Arzneimittel und verwendung derselben zur steuerung der serumcalciumkonzentration bei warmbluetern
US4512925A (en) * 1983-09-14 1985-04-23 Wisconsin Alumini Research Foundation 1,23-Dihydroxyvitamin D compounds
US4769181A (en) * 1983-11-07 1988-09-06 Wisconsin Alumni Research Foundation 1,25-dihydroxyvitamin D2 compounds
US4588716A (en) * 1984-05-04 1986-05-13 Wisconsin Alumni Research Foundation Method for treating metabolic bone disease in mammals
WO1987000834A1 (en) * 1985-08-02 1987-02-12 Leo Pharmaceutical Products Ltd. A/S Novel vitamin d analogues
US5206229A (en) * 1988-04-21 1993-04-27 Leo Pharmaceutical Products Ltd Vitamin d analogues
US5250523A (en) * 1988-04-29 1993-10-05 Wisconsin Alumni Research Foundation Side chain unsaturated 1α-hydroxyvitanim D homologs
US4851401A (en) * 1988-07-14 1989-07-25 Wisconsin Alumni Research Foundation Novel cyclopentano-vitamin D analogs
US4973584A (en) * 1989-03-09 1990-11-27 Deluca Hector F Novel 1α-hydroxyvitamin D2 epimer and derivatives
GB8915770D0 (en) * 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
DE69214617T2 (de) * 1991-12-26 1997-05-28 Wisconsin Alumni Res Found 26,27-Dimethylen-1-Alpha, 25-Dihydroxyvitamin-D2 und 26,27-Dihydroxyvitamin-D2 und Verfahren zu ihrer Herstellung
US5194431A (en) * 1992-07-08 1993-03-16 Wisconsin Alumni Research Foundation 24-cyclopropane vitamin D derivatives

Also Published As

Publication number Publication date
US5373004A (en) 1994-12-13
DK0730577T3 (da) 1999-01-18
EP0730577B1 (en) 1998-05-06
EP0730577A1 (en) 1996-09-11
WO1995014662A1 (en) 1995-06-01
AU8086494A (en) 1995-06-13
JP3681390B2 (ja) 2005-08-10
DE69410112T2 (de) 1999-01-14
ATE165819T1 (de) 1998-05-15
JPH09506343A (ja) 1997-06-24
DE69410112D1 (de) 1998-06-10
US5457217A (en) 1995-10-10

Similar Documents

Publication Publication Date Title
ES2115267T3 (es) Compuestos de 26,28-metilen-1alfa,25-dihidroxivitamina d2.
DE69300196D1 (de) 24-Cyclopropan-Vitamin-D-Derivate.
EP0549318A3 (en) 26,27-dimethylene-1 alpha, 25-dihydroxyvitamin d2 and 26,27-dihydroxyvitamin d2 and methods for preparing same
NO972258D0 (no) 18, 19-dinor-vitamin D-forbindelser
ES2169023T3 (es) Nueva 1alfa-hidroxi vitaminada d4 y nuevos intermedios y analogos.
UY24895A1 (es) Arilsulfonamidas y análogos útiles para el tratamiento de enfermedades neurodegenerativas
MY109928A (en) Fatty acid treatment
ATE127691T1 (de) Verwendung von vitamin-d-analoga zur behandlung von akne.
JPS55500428A (es)
HU902288D0 (en) Process for producing new epimers of 1-alpha-hydroxy-d vitamin and their derivatives as well as pharmaceutical preparatives containing these compounds
AR007241A1 (es) Analogos de 20-epi-16-eno de vitamina d3, composiciones farmaceuticas que los contienen, procedimiento para la preparacion de dichos compuestos yempleo de dichos compuestos para la preparacion de composiciones farmaceuticas
IT1211783B (it) E la prevenzione della osteoporosi composizione di fluoro e calcio a e simili affezioni ossee lento rilascio, per il trattamento
EP1656157A4 (en) 2-METHYLENE-19-NOR-VITAMIN D2 COMPOUNDS
DE3560902D1 (en) Vitamin d3 derivatives
PL350917A1 (en) C16 unsaturated fp-selective prostaglandins analogs
ATE238986T1 (de) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga
ES2041647T3 (es) Metodo para producir un compuesto de oseinahidroxiapatita.
AR033787A2 (es) Compuestos intermediarios para preparar arilsulfonamidas y analogos
BR9508185A (pt) Composto de tetraésteres de ácido piridinil-aminometilideno- bisfônico composição farmacêutica processo para fabricar uma composição farmacêutica e método para tratar doenças ósseas
YU13499A (sh) Primena 1-hidroksi-2-piridona za lečenje seboroitičnog dermatitisa
PE26691A1 (es) Procedimiento de preparacion de azabencimidazoles, utiles en el tratamiento de asma, artritis y enfermedades relacionadas
MX9305506A (es) PROCEDIMIENTO PARA LA OBTENCIóN DE 2,4/2,6-DIAMINO-TOLUENO MIXTO EXENTO DE RESIDUOS.
WO2000010548A3 (en) 19-nor-vitamin d3 compounds with calcemic activity
ES2061293T3 (es) Procedimiento para el acondicionamiento y/o purificacion de isocianatos organicos.
MX9703720A (es) Compuestos de 18-nor-vitamina d.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 730577

Country of ref document: ES